-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$13.00-31.36% Downside
Innoviva, Inc. Frequently Asked Questions
-
What analysts cover Innoviva, Inc.?
Innoviva, Inc. has been rated by research analysts at Morgan Stanley in the past 90 days.